Can-Fite BioPharma (NYSE:CANF) Rating Lowered to “Sell” at StockNews.com

StockNews.com lowered shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a research report released on Wednesday morning.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

Shares of CANF stock opened at $1.97 on Wednesday. The firm has a 50-day moving average of $2.23 and a 200-day moving average of $2.52. Can-Fite BioPharma has a one year low of $1.83 and a one year high of $4.69. The company has a market cap of $6.97 million, a P/E ratio of -1.10 and a beta of 1.39.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the SEC. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.